Allergan wins FDA approval for Latisse

Assam · December 27, 2008

Pharmaceutical firm Allergan Inc., the maker of Botox, said on Friday that the U.S. Food and Drug Administration (FDA) has approved its eyelash-thickening drug Latisse. The approval was based on the solution meeting the endpoints of improved eyelash prominence, length, thickness and darkness in a Phase 3, multi-center, double-masked and placebo controlled study.

Latisse is designed to treat a condition known as hypotrichosis of the eyelashes, which means a person does not have enough eyelashes. The active ingredient in Latisse is bimatroprost, the same ingredient that is in Allergan’s glaucoma treatment Lumigan. Patients taking Lumigan found a side effect of the drug to be eyelash growth, prompting Allergan to study it for the new use.

Allergan’s Latisse is a once a day prescription treatment that is applied to the base of the upper eyelash with a sterile, single-use, per eye disposable applicator. Once the Latisse treatment is stopped, eyelashes will gradually return to where they were prior to treatment.

Share |

Category: Health and Fitness | Tags: Health and Fitness, Latisse